These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1083 related articles for article (PubMed ID: 33517367)
21. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations. Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993 [TBL] [Abstract][Full Text] [Related]
22. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery. Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429 [TBL] [Abstract][Full Text] [Related]
23. Identification of novel inhibitors of SARS-CoV-2 main protease (M Verma S; Patel CN; Chandra M J Comput Chem; 2021 Oct; 42(26):1861-1872. PubMed ID: 34287986 [TBL] [Abstract][Full Text] [Related]
24. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease. Varadharajan V; Arumugam GS; Shanmugam S J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269 [TBL] [Abstract][Full Text] [Related]
25. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2. Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956 [TBL] [Abstract][Full Text] [Related]
26. Molecular docking and dynamics study of natural compound for potential inhibition of main protease of SARS-CoV-2. Mahmud S; Uddin MAR; Zaman M; Sujon KM; Rahman ME; Shehab MN; Islam A; Alom MW; Amin A; Akash AS; Saleh MA J Biomol Struct Dyn; 2021 Oct; 39(16):6281-6289. PubMed ID: 32705962 [TBL] [Abstract][Full Text] [Related]
27. Identification of alkaloids from Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Mol Struct; 2021 Apr; 1229():129489. PubMed ID: 33100380 [TBL] [Abstract][Full Text] [Related]
28. Molecular insights to the binding interactions of APNS containing HIV-protease inhibitors against SARS-CoV-2 M Purohit P; Dash JJ; Muya JT; Meher BR J Biomol Struct Dyn; 2023 Jun; 41(9):3900-3913. PubMed ID: 35388744 [TBL] [Abstract][Full Text] [Related]
29. Some Flavolignans as Potent Sars-Cov-2 Inhibitors Cetin A Curr Comput Aided Drug Des; 2022; 18(5):337-346. PubMed ID: 35975852 [TBL] [Abstract][Full Text] [Related]
30. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621 [TBL] [Abstract][Full Text] [Related]
31. Depicting the inhibitory potential of polyphenols from Ghosh R; Chakraborty A; Biswas A; Chowdhuri S J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085 [TBL] [Abstract][Full Text] [Related]
32. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation. Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783 [TBL] [Abstract][Full Text] [Related]
33. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors. Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249 [TBL] [Abstract][Full Text] [Related]